RecruitingLocally Advanced Urothelial CarcinomaOligo-metastaic Urothelial Carcinoma
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.
Sponsor: Yale University
You may qualify if…
- ✓ 1. Be at least 18 years of age.
- ✓ 2. Have provided informed consent.
- ✓ 3. Have ECOG Performance status of 0 or 1.
- ✓ 4. Be surgical candidate for extirpative surgery of primary site with standard bilateral pelvic lymph node dissection and urinary diversion at the discretion of urological oncologist.
- ✓ 5. If applicable, must be a surgical candidate for resection of non-irradiated metastatic lesion(s) at the discretion of the treating surgeon.
- ✓ 6. Have adequate organ function as defined by:
- ✓ 1. Hgb \>9.0 ng/dL.
- ✓ 2. WBC \>3.0 K/mcL.
You may not qualify if…
- ✕ Participants who meet any of the following criteria will be excluded from study entry.
- ✕ 1. Received systemic anti-cancer therapy within three weeks prior to the surgery.
- ✕ 2. Received radiotherapy within two weeks prior to the surgery.
- ✕ 3. Have a positive serum pregnancy test or women who are breastfeeding.
- ✕ 4. Have other concurrent medical, surgical or psychiatric conditions that, in the treating investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
- ✕ 5. Have any medical condition that, in the treating investigator's opinion, poses an undue risk to the participant's participation in the study.
- ✕ 6. Have history of central nervous system (CNS) metastasis and/or leptomeningeal metastasis.
Where it's recruiting
Connecticut
New Haven
Wisconsin
Madison
Source: ClinicalTrials.gov · NCT07048457 · last updated 2026-10-07